⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LGVN News
Longeveron Inc. Common Stock
Form 8-K
sec.gov
LGVN
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
globenewswire.com
LGVNR
LGVN
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
globenewswire.com
LGVN
Longeveron Announces Closing of Private Placement of up to $30 Million
globenewswire.com
LGVNR
LGVN
Longeveron Announces Private Placement of up to $30 Million
globenewswire.com
LGVNR
LGVN
Longeveron Announces Private Placement of up to $30 Million
globenewswire.com
LGVN
Form 8-K
sec.gov
LGVN
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
prnewswire.com
FBLG
MESO
LGVN
FATE
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
globenewswire.com
LGVNR
LGVN
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
globenewswire.com
LGVNR
LGVN